MedTrace Logo

Treatment Success With the CoolLoop Cryoablation System

NCT03818724 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 540

Last updated 2022-07-21

No results posted yet for this study

Summary

This clinical study evaluates the safety and efficacy of the treatment with the CoolLoop® cryoablation System (sclerotherapy of muscle tissue of the heart by freezing) in patients with atrial fibrillation (permanent atrial fibrillation excepted) over a follow-up period of 36 months.

A further aim of this study is to evaluate the average duration of procedure and fluoroscopy times.

Conditions

Interventions

DEVICE

CoolLoop® cryoablation system

Cryoablation of Atrial Fibrillation using the CoolLoop® Cryoablation System

Sponsors & Collaborators

  • Raffeiner GmbH

    collaborator INDUSTRY

  • afreeze GmbH

    lead OTHER

Principal Investigators

  • Andreas Kaiser, PhD · afreeze GmbH

  • Florian Hintringer, MD · Medical University Innsbruck

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-17
Primary Completion
2025-01-31
Completion
2025-01-31

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03818724 on ClinicalTrials.gov